BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 31776976)

  • 1. Long-term clinical outcomes of papillary thyroid carcinoma patients with biochemical incomplete response.
    Ahn J; Song E; Kim WG; Kim TY; Kim WB; Shong YK; Jeon MJ
    Endocrine; 2020 Mar; 67(3):623-629. PubMed ID: 31776976
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Individualized Follow-Up Strategy for Patients with an Indeterminate Response to Initial Therapy for Papillary Thyroid Carcinoma.
    Oh HS; Ahn JH; Song E; Han JM; Kim WG; Kim TY; Kim WB; Shong YK; Jeon MJ
    Thyroid; 2019 Feb; 29(2):209-215. PubMed ID: 30384812
    [TBL] [Abstract][Full Text] [Related]  

  • 3. UNFAVORABLE RESPONSES TO RADIOIODINE THERAPY IN N1B PAPILLARY THYROID CANCER: A PROPENSITY SCORE MATCHING STUDY.
    Liu YQ; Li H; Liu JR; Lin YS
    Endocr Pract; 2019 Dec; 25(12):1286-1294. PubMed ID: 31412228
    [No Abstract]   [Full Text] [Related]  

  • 4. Dynamic Risk Estimates of Outcome in Chinese Patients with Well-Differentiated Thyroid Cancer After Total Thyroidectomy and Radioactive Iodine Remnant Ablation.
    Shen FC; Hsieh CJ; Huang IC; Chang YH; Wang PW
    Thyroid; 2017 Apr; 27(4):531-536. PubMed ID: 28007013
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of post-ablation stimulated thyroglobulin in differentiated thyroid cancer patients with biochemical incomplete response: a bi-center observational study.
    Wang Y; Wu J; Jiang L; Zhang X; Liu B
    Endocrine; 2022 Apr; 76(1):109-115. PubMed ID: 35094313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PROGNOSIS OF HIGH-RISK PAPILLARY THYROID CANCER PATIENTS WITH PRE-ABLATION STIMULATED TG <1 NG/ML.
    Tian T; Kou Y; Huang R; Liu B
    Endocr Pract; 2019 Mar; 25(3):220-225. PubMed ID: 30913010
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes of patients with differentiated thyroid cancer risk-stratified according to the American thyroid association and Latin American thyroid society risk of recurrence classification systems.
    Pitoia F; Bueno F; Urciuoli C; Abelleira E; Cross G; Tuttle RM
    Thyroid; 2013 Nov; 23(11):1401-7. PubMed ID: 23517313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Indication for radioactive iodine in patients with papillary thyroid carcinoma without apparent disease after total thyroidectomy but with elevated antithyroglobulin antibodies.
    Ramos da Silva F; Rosario PW; Mourão GF
    Clin Endocrinol (Oxf); 2022 Jan; 96(1):82-88. PubMed ID: 34323308
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thyroid autoimmunity, thyroglobulin autoantibodies, and thyroid cancer prognosis.
    Viola N; Agate L; Caprio S; Lorusso L; Brancatella A; Ricci D; Sgrò D; Ugolini C; Piaggi P; Vitti P; Elisei R; Santini F; Latrofa F
    Endocr Relat Cancer; 2023 Jul; 30(7):. PubMed ID: 37043372
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Postoperative stimulated thyroglobulin of less than 1 ng/ml as a criterion to spare low-risk patients with papillary thyroid cancer from radioactive iodine ablation.
    Rosario PW; Mineiro Filho AF; Prates BS; Silva LC; Calsolari MR
    Thyroid; 2012 Nov; 22(11):1140-3. PubMed ID: 23050786
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radioactive Iodine Therapy Decreases the Recurrence of Intermediate-Risk PTC With Low Thyroglobulin Levels.
    Tian T; Qi Z; Huang S; Wang H; Huang R
    J Clin Endocrinol Metab; 2023 Jul; 108(8):2033-2041. PubMed ID: 36715264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of changes in serum thyroglobulin antibody levels of pre- and post-total thyroidectomy in thyroglobulin antibody-positive papillary thyroid carcinoma patients.
    Tsushima Y; Miyauchi A; Ito Y; Kudo T; Masuoka H; Yabuta T; Fukushima M; Kihara M; Higashiyama T; Takamura Y; Kobayashi K; Miya A; Kikumori T; Imai T; Kiuchi T
    Endocr J; 2013; 60(7):871-6. PubMed ID: 23585494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Natural history, predictive factors of apparent disease (structural or biochemical) and spontaneous excellent response in patients with papillary thyroid carcinoma and indeterminate response to initial therapy with radioiodine.
    Rosario PW; Mourão GF
    Endocrine; 2022 Jun; 76(3):671-676. PubMed ID: 35347578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Papillary thyroid carcinomas with biochemical incomplete or indeterminate responses to initial treatment: repeat stimulated thyroglobulin assay to identify disease-free patients.
    Lamartina L; Montesano T; Trulli F; Attard M; Torlontano M; Bruno R; Meringolo D; Monzani F; Tumino S; Ronga G; Maranghi M; Biffoni M; Filetti S; Durante C
    Endocrine; 2016 Nov; 54(2):467-475. PubMed ID: 26668060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes of total thyroidectomy with therapeutic central and lateral neck dissection with a single dose of radioiodine in the treatment of regionally advanced papillary thyroid cancer and effects on serum thyroglobulin.
    Hughes DT; Miller BS; Cohen MS; Doherty GM; Gauger PG
    Ann Surg Oncol; 2014 May; 21(5):1647-52. PubMed ID: 24385210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Papillary thyroid carcinoma patients assessed to be at low or intermediary risk after primary treatment are at greater risk of long term recurrence if they are thyroglobulin antibody positive or do not have distinctly low thyroglobulin at initial assessment.
    Soyluk O; Boztepe H; Aral F; Alagol F; Özbey NC
    Thyroid; 2011 Dec; 21(12):1301-8. PubMed ID: 22136265
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in serum thyroglobulin antibody levels as a dynamic prognostic factor for early-phase recurrence of thyroglobulin antibody-positive papillary thyroid carcinoma after total thyroidectomy.
    Yamada O; Miyauchi A; Ito Y; Nakayama A; Yabuta T; Masuoka H; Fukushima M; Higashiyama T; Kihara M; Kobayashi K; Miya A
    Endocr J; 2014; 61(10):961-5. PubMed ID: 25029954
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Follow-Up Strategy for Patients with an Excellent Response to Initial Therapy for Differentiated Thyroid Carcinoma: Less Is Better.
    Jeon MJ; Kim M; Park S; Oh HS; Kim TY; Kim WB; Shong YK; Kim WG
    Thyroid; 2018 Feb; 28(2):187-192. PubMed ID: 29179642
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low postoperative nonstimulated thyroglobulin as a criterion to spare radioiodine ablation.
    Mourão GF; Rosario PW; Calsolari MR
    Endocr Relat Cancer; 2016 Jan; 23(1):47-52. PubMed ID: 26503963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reoperative lymph node dissection for recurrent papillary thyroid cancer and effect on serum thyroglobulin.
    Hughes DT; Laird AM; Miller BS; Gauger PG; Doherty GM
    Ann Surg Oncol; 2012 Sep; 19(9):2951-7. PubMed ID: 22526913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.